| 18.0 |
Nuclear Medicine |
| 18.1 |
Patient Care |
| 18.1.1 |
Patient Education |
| 18.1.2 |
Nuclear Medicine Questionnaire |
| 18.1.3 |
Policy for Pregnant or Possible Pregnant patients |
| 18.1.5 |
Nuclear Medicine Appropriateness Indicators |
| 18.1.6 |
Nuclear Medicine Dose Schedule for Adults |
| 18.1.7 |
Pediatric Dose Schedule |
| 18.1.8 |
Nuclear Medicine I.V. Access Policy |
| 18.2 |
General Policies - Personnel and Lab |
| 18.2.1 |
Policy for Pregnant Worker in Nuclear Medicine |
| 18.2.2 |
Declaration of Pregnancy |
| 18.2.4 |
Regulations of Nuclear Medicine Personnel |
| 18.2.5 |
Misadministration of Radiopharmaceutical |
| 18.2.6 |
Personnel in NM to Inject Patients |
| 18.2.6.1 |
Bioassay Procedure |
| 18.2.6.2 |
Quality Control in Radiopharmacological Laboratory |
| 18.3 |
Radioactive Materials Management |
| 18.3.1 |
Theft or Loss Radioactive Materials |
| 18.4 |
Quality Assurance & Maintenance Procedures |
| 18.4.1 |
Equipment PM Schedule |
| 18.5 |
Area Monitoring and Wipe Test |
| 18.6 |
Decontamination |
| 18.7 |
Quality Management Program |
| 18.8 |
Nuc Med Procedures |
| 18.8.1 |
Enodocrine System |
| 18.8.1.1 |
Thyroid Uptake |
| 18.8.1.2 |
Interfering Chemicals and Drugs |
| 18.8.1.3 |
I-123 Thryroid Scintigraphy |
| 18.8.1.4 |
Tc99m Pertechnetate Thyroid Scintigraphy |
| 18.8.1.5 |
I-131 Whole Body Scintigraphy |
| 18.8.1.6 |
I-131 Whole Body (Uptake) Retention |
| 18.8.1.7 |
Differentiated Thyroid Cancer Scintigraphy |
| 18.8.1.8 |
Parathyroid Scintigrahy |
| 18.8.1.9 |
I-31 MIBG Scintigraphy |
| 18.8.1.10 |
I-131 Therapy of Hyperthyroidism |
| 18.8.1.11 |
Radiation Safety During Iodine Therapy over 30 mCi
(Inpatient) |
| 18.8.1.12 |
Nursing Instructions for Patients Treated with I-131 |
| 18.8.1.13 |
Radiation Safety Checklist for I-131 Therapy over 30 mCi
(Inpatient) |
| 18.8.1.14 |
Radiation Safety Instructions for Nursing Personnel
Participating in I-131 Treatment |
| 18.8.1.15 |
Room Survey and Instructions |
| 18.8.1.16 |
Room Release survey form |
| 18.8.1.17 |
Release of I-131 Patients |
| 18.8.1.18 |
Physician Written Directive for Radiopharmaceutical Dose |
| 18.8.1.19 |
Criteria for Early Release of Patient (>33 mCi I-131) |
| 18.8.1.20 |
Thyroid Carcinoma Therapy Release Determination |
| 18.8.1.21 |
Immediate Release Dose Calculations |
| 18.8.1.22 |
Instructions to Patients Who Have Received Radioactive
Material |
| 18.8.1.23 |
Records for Release of Radioactive Patients |
| 18.8.1.24 |
Hyperthyroid Pts Safety instructions (Dose is 7 mCi) |
| 18.8.1.25 |
Hyperthyroid Pts Safety Instructions,Dose is 7 mCi-15 mCi |
| 18.8.1.26 |
Hyperthyroid Pts Safety Instructions, Dose is 16 mCi-15 mCi |
| 18.8.1.27 |
Hyperthyroid Pts Safety Instructions, Dose is 34 mCi-15 mCi |
| 18.8.1.28 |
Carcinoma Patients Safety Instructions, Dose < 33mCi |
| 18.8.1.29 |
Carcinoma Patients Safety Instructions, Dose is 33 mCi - 100 mCi |
| 18.8.1.30 |
Carcinoma Patients Safety Instructions, Dose is 101 mCi - 150 mCi |
| 18.8.1.31 |
Carcinoma Patients Safety Instructions, Dose is 151 mCi - 200 mCi |
| 18.8.1.32 |
Instructions to Nursing Mothers who have received
Radioactive Materials |
| 18.8.2 |
Hematopoietic, Reticuloendothelial and Lymphatic System |
| 18.8.2.1 |
Bone Marrow Scintigraphy |
| 18.8.2.2 |
Lymphuscintigraphy for Breast Cancer |
| 18.8.2.3 |
Lymphoscintigraphy for Melanoma and Other skin cancers |
| 18.8.2.4 |
Spleen Imaging |
| 18.8.3 |
Gastrointestinal System |
| 18.8.3.1 |
Tc99m Labeled Red Blood Cells for Evaluation Hepatic
Hemangioma |
| 18.8.3.2 |
Liver Spleen Scintigraphy (Reticuloendothelial Function) |
| 18.8.3.3 |
Liver Scan, Biliary Function |
| 18.8.3.4 |
Liver Scan, Biliary Function with EF |
| 18.8.3.5 |
Salivary Gland Scitigraphy
|
| 18.8.3.6 |
Esophageal Reflux/Pulmonary Aspiration Scintigraphy |
| 18.8.3.7 |
Pediatric Gastroesophageal Reflux Study (Milk Scan) |
| 18.8.3.8 |
Gastric Emptying Imaging |
| 18.8.3.9 |
Acute GI Bleed (In Vitro Method) |
| 18.8.3.10 |
Intestinal Imaging (Ectopic gastric Mucosa) - Meckels |
| 18.8.3.11 |
Peritoneovenous Shunt Study (Denver Shunt) |
| 18.8.3.12 |
Peritoneal Cavity Scintigraphy
|
| 18.8.4 |
Musculoskeletal System |
| 18.8.4.1 |
Bone Scintigraphy |
| 18.8.4.2 |
Reflex Sympathetic Dystrophy Syndrome Imaging |
| 18.8.5 |
Cardiovascular System |
| 18.8.5.1 |
Myocardial Perfusion Stress Protocol Dual Tracer |
| 18.8.5.2 |
Resting TI-201 (Viability) Myocardial Imaging |
| 18.8.5.3 |
Stress Rest TI-201 Imaging |
| 18.8.5.4 |
Resting Tc99m tertofosmin Imaging |
| 18.8.5.5 |
Tc99m Stress Rest Imaging |
| 18.8.5.6 |
Gated Blood Pool Study (MUGA) |
| 18.8.5.7 |
First Pass for Quantification of a Left to Right Shunt |
| 18.8.5.8 |
Myocardial Infarct Imaging |
| 18.8.6 |
Respiratory System |
| 18.8.6.1 |
Pulmonary Perfusion Scintigraphy |
| 18.8.6.2 |
Aerosol Ventilation Scintigraphy |
| 18.8.6.3 |
Xenon Ventilation Scitigraphy |
| 18.8.6.4 |
Ventilation and Perfusion Lung Scan |
| 18.8.6.5 |
Quantitative Xenon Ventilation Scinitigraphy |
| 18.8.6.6 |
Pulmonary Shunt |
| 18.8.6.7 |
Safety Regulations for Xenon 133 Gass |
| 18.8.7 |
Nervous System |
| 18.8.7.1 |
Radionuclide Cerebral Imaging for Brain Death |
| 18.8.7.2 |
Brain Scan |
| 18.8.7.3 |
Brain Perfusion SPECT Imaging |
| 18.8.7.4 |
Cisternography |
| 18.8.7.5 |
CSF Leak Imaging |
| 18.8.7.6 |
CSF Shunt Patency |
| 18.8.7.7 |
Dacryocystography |
| 18.8.8 |
Genitourinary System |
| 18.8.8.1 |
Renal Scintigraphy |
| 18.8.8.2 |
Transplant Renal Imaging |
| 18.8.8.3 |
Renal Cortical (DMSA) Scintigraphy |
| 18.8.8.4 |
Gates Method (GFR) Imaging |
| 18.8.8.5 |
Duretic (LASIX) Renal Scintigraphy |
| 18.8.8.6 |
ACE-Inhibited (CAPTOPRIL) Renal Scintigraphy |
| 18.8.8.7 |
ACE Inhibitor List |
| 18.8.8.8 |
Urethral reflux Study (Radionuclide Cystogram) |
| 18.8.8.9 |
Cystogram Data Sheet |
| 18.8.8.10 |
Testicular Scan |
| 18.8.9 |
Tumor and Abscess Imaging |
| 18.8.9.1 |
Radiopharmaceutical Selection for Infection/Inflammation
Imaging |
| 18.8.9.2 |
White Blood Cell Scan (In-111 oxine) |
| 18.8.9.3 |
Tc99m White Blood Cell Imaging |
| 18.8.9.4 |
Gallium Imaging |
| 18.8.9.5 |
Octreotide (Somatostatin-Receptor)Imaging |
| 18.8.9.6 |
Prostatic Tumor (Prostascint) Imaging |
| 18.8.10 |
Therapeutic Procedures |
| 18.8.10.1 |
Sr-89 Chloride Therapy |
| 18.8.10.2 |
Sm-153 EDTMP (Quadramet) Therapy |
| 18.8.10.3 |
Zevalin Therapy |
| 18.8.10.4 |
Treatment of Ovarian Carcinoma with P32 |
